Puerto Rico is emerging as a key biopharma hub, offering advanced manufacturing capabilities, a highly skilled workforce, and significant cost advantages. In this conversation, OcyonBio CEO Robert Salcedo discusses how his company is leveraging AI-driven manufacturing, modular wet labs, and strategic infrastructure to support biotech and gene therapy companies.

Colorectal cancer remains the second leading cause of cancer deaths, with disparities in screening and care access posing major challenges. At the 2024 STAT Summit, Dr. Angie Nicholas and Dr. Fola May discussed how real-world data and collaboration among diverse stakeholders is driving efforts to close these gaps and achieve ambitious goals like 80% screening rates by 2030.

NYU Grossman School of Medicine is transforming medical education with an innovative three-year medical degree and tuition-free enrollment. Senior Associate Dean Joan Cangiarella, M.D., highlights the school's commitment to curriculum reform and personalized learning pathways designed to equip students for their preferred specialties while eliminating financial barriers to entry.

Molecular testing tools, including tumor sequencing and increasingly sensitive diagnostics, are leveling up oncology by enabling precise, personalized cancer treatment. Clinicians can now detect circulating tumor DNA, assess patients' cancer risk, monitor for resistance mutations, and adjust treatments in real time.

Dr. Alec Kimmelman, director of the Perlmutter Cancer Center, discusses how NYU Langone’s integrated infrastructure enhances data-driven clinical decisions and contributes to groundbreaking cancer research.

As CEO of NYU Langone Health and dean of the Grossman School of Medicine, Dr. Robert Grossman leads a health system that excels in patient-oriented metrics, with a strategic eye toward the future. In this STAT Brand Studio podcast, he details the organization's landmark accomplishments over the last 17 years and singular culture rooted in respect for employees and patients.

It doesn’t take a rocket scientist to see that getting new health technologies to market is incredibly hard, with companies in biotech and health tech falling apart as the funding environment worsens. By gathering real operators from the trenches who have not previously spoken out, not just talking heads, we’ll cover some of the biggest challenges faced by those who want to move advances out of the lab and into the world.We’ll discuss everything from drug development and technology invention to dealing with regulators, courting investors, and pricing and selling products.